2. NF-κB
  3. RANKL/RANK

RANKL/RANK

Receptor activator of NF-κB (RANK) and its ligand receptor activator of NF-κB ligand (RANKL) are encoded, respectively, by the Tumor necrosis factor receptor superfamily member 11A (Tnfrsf11a) and the Tumor necrosis factor ligand superfamily member 11 (Tnfsf11) genes, RANK and RANKL constitute a receptor-ligand pair initiating a signaling pathway of paramount relevance in bone remodeling, lymph node formation, establishment of the thymic microenvironment, mammary gland development during pregnancy, and bone metastasis in cancer. RANK mutant mice, as well as RANKL mutant mice, exhibit severe osteopetrosis and defective tooth eruption due to a complete lack in osteoclast. Moreover, RANKL and RANK mutant mice lack lymph nodes and AIRE+ thymic medullary epithelial cells.

RANKL/RANK Related Products (8):

Cat. No. Product Name Effect Purity
  • HY-151346
    sRANKL-IN-2 Inhibitor 99.65%
    sRANKL-IN-2 (Compound S3-05) is a selective and orally active soluble RANKL (sRANKL) inhibitor with an IC50 of 0.41 μM. sRANKL-IN-2 can be used for the research of osteoporosis[1].
  • HY-N10117
    2,3-Bis(3-indolylmethyl)indole
    2,3-Bis(3-indolylmethyl)indole significantly suppresses RANKL-induced osteoclast formation, actin ring formation, and bone resorption in a concentration-dependent manner.
  • HY-N6973
    Boldine 99.68%
    Boldine is an aporphine isoquinoline alkaloid extracted from the root of Litsea cubeba and also possesses these properties, including antioxidant, anti-inflammatory and cytoprotective effects. Boldine suppresses osteoclastogenesis, improves bone destruction by down-regulating the OPG/RANKL/RANK signal pathway and may be a potential therapeutic agent for rheumatoid arthritis[1].
  • HY-151347
    sRANKL-IN-3 Inhibitor 98.95%
    sRANKL-IN-3 (Compound S3-15) is a potent, orally active and selective soluble RANKL (sRANKL) inhibitor with an IC50 of 0.19 μM. sRANKL-IN-3 can be targeted to inhibit soluble RANK-RANKL interactions. sRANKL-IN-3 can be used for the research of osteoporosis[1].
  • HY-N0499
    Cyanidin Chloride
    Cyanidin Chloride (IdB 1027), a subclass of anthocyanin, displays antioxidant and anti-carcinogenesis properties. Cyanidin Chloride (IdB 1027) inhibits osteoclast formation, hydroxyapatite resorption, and receptor activator of NF-κB ligand (RANKL)-induced osteoclast marker gene expression[1].
  • HY-151345
    sRANKL-IN-1 Inhibitor
    sRANKL-IN-1 (compound S3) is a sRANKL (soluble RANKL) inhibitor. sRANKL-IN-1 shows a potent osteoclast inhibition effect with an IC50 value of 0.096 μM and a KD value of 34.80 μM. sRANKL-IN-1 can be used for the research of osteoporosis[1].
  • HY-N10062
    Amakusamine Inhibitor
    Amakusamine inhibits the receptor activator of nuclear factor-κB ligand (RANKL)-induced formation of multinuclear osteoclasts with an IC50 value of 10.5 μM in RAW264 cells.
  • HY-N1746
    (2S)-2'-Methoxykurarinone
    (2S)-2'-Methoxykurarinone, a compound isolated from the roots of Sophora flavescens, has anti-inflammatory, antipyretic, antidiabetic, and antineoplastic effects. (2S)-2'-Methoxykurarinone (MK) inhibits osteoclastogenesis and bone resorption through down-regulation of RANKL signaling. (2S)-2'-Methoxykurarinone (MK) displays cytotoxic activity against human myeloid leukemia HL-60 cells[1][2].